MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.gastrohep.2015.07.002

Медицинская библиотека · Gastroenterologia y hepatologia · 2015

[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].

Giménez-Manzorro Álvaro, García-González Xandra, Rodríguez-González Carmen Guadalupe, Ochoa-Palominos Alejandra, Sanjurjo-Sáez María, Clemente-Ricote Gerardo

Сравнительное исследованиеСтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Triple therapy with telaprevir or boceprevir has proven to be effective in the treatment of chronic hepatitis C with response rates of up to 88%. However, the treatment may be associated with important adverse effects and a high economic impact.

OBJECTIVE

To assess the cost-effectiveness and safety of triple therapy with telaprevir or boceprevir for the treatment of chronic hepatitis C.

METHODS

Retrospective observational study. We included all patients who had started treatment with protease inhibitors before July 31(st), 2013. We evaluated sustained virological response, the cost per patient achieving sustained virological response, and the cost of the supportive treatment for adverse events associated with triple therapy.

RESULTS

Fifty-nine patients were included; 35 had been treated with telaprevir (59.3%) and 24 with boceprevir (40.7%). Sustained virological response was achieved by 38 (64.4%) patients: 24 (68.6%) patients in the telaprevir treatment arm and 14 (58.3%) patients in the boceprevir treatment arm. The cost per patient with sustained virological response was 43,555 € (95% CI 35,389-51,722 €). There were no statistically significant differences between the overall costs of therapy with telaprevir, 43,494 € (95% CI 34,795 €-55,092 €) versus boceprevir, 42,005 € (95% CI 32,122-64,243€). The mean cost of supportive care per patient was 1,500 €, while the maximum cost was 11,374 €. Due to adverse events, 8 (13.6%) patients required hospital admission, 22 (37.3%) patients attended the accident and emergency department, and 26 (44.1%) patients needed additional medical consultations.

CONCLUSIONS

The treatment of triple therapy with telaprevir or boceprevir resulted in high cost per patient with sustained virological response. Due to adverse events, a high number of patients required supportive care, whose costs should be added to those of triple therapy.

Для цитирования: Giménez-Manzorro Álvaro, García-González Xandra, Rodríguez-González Carmen Guadalupe, Ochoa-Palominos Alejandra, Sanjurjo-Sáez María, Clemente-Ricote Gerardo. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].. Gastroenterologia y hepatologia. 2015. DOI: 10.1016/j.gastrohep.2015.07.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.